Pharmacologic manipulation of a four day murine delayed type hypersensitivity model

The specificity of JAK3 kinase inhibitors

PF-956980 is a selective inhibitor of JAK3, related in structure to CP-690550, a compound being evaluated in clinical trials for rheumatoid arthritis and prevention of allograft rejection. PF-956980 has been evaluated against a panel of 30 kinases, and found to have nanomolar potency against only JAK3. Cellular and whole blood activity of this compound parallels its potency and selectivity in enzyme assays. It was effective in vivo at inhibiting the delayed type hypersensivity reaction in mice. We compared 2 commercially available JAK3 inhibitors (WHI-P131 and WHI-P154) in the same panel of biochemical and cellular assays and found them to be neither potent nor selective for JAK3. Both were found to be nanomolar inhibitors of the EGF receptor family of kinases. As these compounds have been used in numerous publications in the transplant and autoimmune disease literature, their specificity should be considered when interpreting these results.

The novel JAK-3 inhibitor CP-690550 is a potent immunosuppressive agent in various murine models

JAK-3 has been shown to play a key role in cytokine signaling via gammac, e.g. IL-2, 4, 7, 9, 15, 21. The current study describes the immunosuppressive effects of CP-690550, a novel, small molecule inhibitor of JAK-3, in various murine models. In vitro, CP-690550 effectively inhibited a murine mixed lymphocyte reaction (MLR) (IC50= 91 nm). Mice chronically dosed with CP-690550 (1.5-15 mg/kg/day) demonstrated dose- and time-dependent alterations in lymphocyte subsets when examined by flow cytometry. The most dramatic change observed was a 96% reduction in splenic NK1.1 + TCRbeta- cell numbers following 21 days of treatment. Delayed-type hypersensitivity (DTH) responses in sensitized mice were reduced in a dose-dependent manner following treatment with the JAK-3 inhibitor (1.87-30 mg/kg, s.c.). Extended survival of neonatal Balb/c hearts implanted into the ear pinna of MHC mismatched C3H/HEN mice was observed with CP-690550 monotherapy (10-30 mg/kg/day), but improved upon combination with cyclosporin (10 mg/kg/day). These data support the participation of JAK-3 in various lymphocyte homeostatic functions in mature mice. Furthermore, the ability of CP-690550 to extend cardiac allograft survival in murine models suggests it may afford a new treatment for prevention of transplant rejection.

Role of central 5-HT(2) receptors in fluoxetine-induced decreases in T lymphocyte activity

Previous studies have demonstrated that fluoxetine administration decreases mitogen-induced T lymphocyte proliferation. The present studies were carried out to determine which receptor subtype(s) was involved and whether these effects on lymphocyte responses were centrally or peripherally mediated. Two hours following administration of the 5-HT(1A) agonist 8-OH-DPAT (1 mg/kg), there was no change in lymphocyte proliferation responses, whereas the 5-HT(2) agonist DOI (2.5 mg/kg) significantly decreased (80%) proliferation. Similarly, pretreatment with the 5-HT(2) antagonists ritanserin (5 mg/kg, 30 min) or ketanserin (5 mg/kg, 1 h) was found to completely antagonize the effects of fluoxetine on lymphocyte proliferation. Consistent with central 5-HT(2) receptor involvement, microinjection of DOI (50 microg) resulted in a decrease in lymphocyte proliferation similar to that observed following systemic administration. Furthermore, central administration of ketanserin (20 microg) prevented the suppressive effects of systemic fluoxetine. Collectively, these results suggest that decreases in mitogen-induced lymphocyte proliferation following acute fluoxetine administration was due to indirect effects of fluoxetine following the activation of central 5-HT(2) receptors.

Suppression of cytotoxic T lymphocyte activity by 2,3,7,8-tetrachlorodibenzo-p-dioxin occurs in vivo, but not in vitro, and is independent of corticosterone elevation

Previous studies have shown that 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) is a potent immunosuppressive compound. In our laboratory, TCDD and structurally related polychlorinated biphenyls (PCBs) have been shown to suppress alloantigen-specific cytotoxic T lymphocyte (CTL) activity in C57B1/6 mice. PCB-induced CTL suppression occurs coincident with significant elevation of plasma glucocorticoid (GC) levels (> 500 ng/ml). Since GC elevation can cause immune suppression, this study was conducted to determine if TCDD-induced CTL suppression is correlated with elevation of plasma corticosterone (CS), the major GC in mice. Single oral doses of TCDD (2.5-40 micrograms/kg) induced a dose-dependent suppression of CTL activity with a calculated 50% immunosuppressive dose (ID50) occurring at 7.2 micrograms/kg. When total lytic units (LU)/spleen were calculated, the ID50 was 2.8 micrograms/kg. In contrast, plasma CS levels were not significantly altered at doses below 40 micrograms/kg. These data suggest that TCDD-induced CTL suppression is not dependent on CS elevation. The direct effect of TCDD on CTL generation was tested by adding TCDD at 10(-13)-10(-9) M to in vitro mixed lymphocyte-tumor cell (MLTC) cultures. No alteration of CTL activity was observed after 5 days of culture at any TCDD concentration. In contrast, CS alone significantly suppressed CTL activity in vitro. CS-induced CTL suppression in vitro was neither enhanced nor inhibited by the presence of TCDD. These results suggest that TCDD causes CTL suppression in vivo by a mechanism that does not involve CS.